Mon, Dec 22, 2014, 9:33 AM EST - U.S. Markets close in 6 hrs 27 mins


% | $
Quotes you view appear here for quick access.

Santarus, Inc. (SNTS) Message Board

  • pharmacule pharmacule Sep 20, 2011 3:44 PM Flag

    Regarding the Safety Study

    Can someone remind me why the safety study only included a 6mg dosage if the FDA filing is for only a 9mg dosage?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Not sure, no mention today in the presentation.

      I thought they were using the 9 mg dose for induction of remission over 8 weeks and 6 mg dose to maintain patients. I know they talked about it in one of the previous presentations.

      I am going to try to find it, but it may take some time.

      Anyone else know why?


      • 1 Reply to contrarian11
      • Why did they choose to use 6 mg instead of 9 mg, for safety?

        BTW- all of these studies agreed upon with the FDA through a SPA, which SNTS has followed.

        The 9 mg dose significantly induces remission (the primary indication, better than current therapies), while 6 mg dose does not in the 8 week study. The 6 mg dose was safe over 12 months (when given to patients after receiving the 9 mg dose in the induction of remission study), but was not effective in maintaining remission (the study was not powered to show this, significantly). Trend to longer relapse for patients on budesonide MMX vs. placebo.

        The NDA filing will be a 505 2b filing for using the 9 mg budesonide MMX dose for inducing remission. This being the case, they can reference all of the data used for Entocort EC, so should be OK as that was safe and effective for treating Crohn's Disease at the 9 mg dose.

        Just wish they would clarify the use of the 6 mg dose better, in light of the new results.

        GLTA longs